# Novo Nordisk account plan

> Novo Nordisk is a Danish obesity and diabetes drugmaker (Ozempic, Wegovy) with DKK 309,064 million of 2025 net sales and 69,505 employees.

## At a glance

Novo Nordisk is a Danish healthcare company founded in 1923 that develops, manufactures and sells treatments for obesity, diabetes and rare blood and endocrine disorders, built on semaglutide (Ozempic, Rybelsus, Wegovy, Wegovy pill). Its medicines reached 45.6 million people in 2025, and 99.1% of sales are realised outside Denmark. FY 2025 net sales were DKK 309,064 million (+10% at CER), operating profit DKK 127,658 million and net profit DKK 102,434 million. It had 69,505 employees at end 2025. The company is controlled by the Novo Nordisk Foundation through Novo Holdings A/S, and its B shares trade on Nasdaq Copenhagen and as ADRs on the NYSE.

## Business units

- **Obesity and Diabetes care** (about 94% of 2025 net sales (DKK 289,456 million)): Obesity care (Wegovy injectable, Wegovy pill, Saxenda) grew 31% at CER to DKK 82,347 million in 2025, while diabetes care (Ozempic, Rybelsus, insulins) was DKK 207,109 million, +4% at CER. The segment's operating margin was 43.7%; in H1 2026 obesity care grew 19% at CER and diabetes care fell 5%.
- **Rare disease** (about 6% of 2025 net sales (DKK 19,608 million)): Rare blood disorders (NovoSeven, NovoEight, Alhemo) and rare endocrine disorders (Norditropin, Sogroya), plus hormone replacement therapy. Sales grew 9% at CER in 2025 with a 6.2% operating margin.

## Strategic priorities

- **Focus on obesity and diabetes**: The strategy was refocused in 2025 on leading in obesity, diabetes and related comorbidities through patient centricity, innovation and affordable access, plus rare blood and endocrine disorders.
- **Full obesity portfolio**: Build options across efficacy, delivery and price: Wegovy pill (16.6% weight loss), Wegovy 7.2 mg (20.7%), CagriSema (US decision expected end 2026), cagrilintide and zenagamtide in phase 3.
- **US access and direct-to-consumer**: Reach patients through NovoCare Pharmacy, telehealth partners, CVS, Amazon Pharmacy and subscriptions, with self-pay prices from USD 149-299 a month for the pill and a US list price of USD 675 for Wegovy and Ozempic from 1 January 2027.
- **Transformation and savings**: About 9,000 jobs cut for around DKK 8 billion of annual savings from 2026, redirected to obesity and diabetes; the savings are ahead of plan.
- **Manage semaglutide loss of exclusivity**: Outside the US, launch second brands in lower-priced segments, fast-track devices and sharpen channels as semaglutide loses exclusivity in markets such as Canada, Brazil and China.

## Latest results

In H1 2026 adjusted sales were DKK 148,551 million, +2% at CER, with Q2 adjusted sales of DKK 78,488 million, +7% at CER, and Q2 adjusted operating profit of DKK 33,389 million, +11%. Reported Q2 operating profit fell 16% after DKK 6.3 billion of pipeline impairments. US Operations adjusted sales fell 4% at CER on lower prices while International Operations grew 8%, with obesity care +40%. The Wegovy pill passed 5 million US prescriptions since its January launch. Guidance was raised to 0% to -6% at CER for adjusted sales and operating profit growth, with free cash flow of DKK 45-55 billion.

## Investments and deals

- **Manufacturing capacity**: Capex of DKK 60.1 billion in 2025 for API and fill-finish capacity and around DKK 55 billion planned for 2026; about USD 2 billion invested in US manufacturing in 2025 and a further USD 5.6 billion planned towards 2028.
- **Akero acquisition**: Intangible asset purchases of DKK 30.0 billion in 2025, mainly Akero Therapeutics and its phase 3 MASH candidate efruxifermin.
- **In-licensing**: UBT251 from The United Laboratories, four oral programmes from Septerna, zaltenibart from Omeros and Lexicon's LX9851.
- **Shareholder returns**: A dividend of DKK 11.70 per share for 2025 and a share buyback of up to DKK 15 billion over 12 months; DKK 41.2 billion returned in H1 2026.

## Challenges and risks

- **Lower US prices**: The MFN agreement, a growing self-pay mix (about 35% of injectable Wegovy) and market-access investment cut realised prices; injectable Wegovy US sales fell 22% at CER in Q2 2026.
- **Semaglutide dependency and loss of exclusivity**: Semaglutide is the vast majority of revenue, and its exclusivity ends in some markets in 2026, with the China compound patent expiring that year.
- **Competition and compounders**: Branded competitors and mass compounders compete in a market the CEO likens to fast consumer goods; CagriSema trailed tirzepatide in a head-to-head study.
- **Pipeline setbacks**: The ZEUS trial of ziltivekimab missed its primary endpoint, monlunabant was terminated, and Evoke in Alzheimer's failed.
- **Margin pressure**: The Q2 2026 adjusted gross margin fell to 78.2% from 82.7% on lower prices and about DKK 3 billion of one-time costs to right-size manufacturing capacity agreements.

## What leadership says

> "The Wegovy® product portfolio remains a key growth driver for Novo Nordisk in 2026, led by the continued rapid adoption of Wegovy® pill in the US" — Maziar Mike Doustdar, President and CEO, Financial report for the first six months of 2026, 4 August 2026

> "price reduction in some ways, is our investment for the future and for capturing more patients" — Maziar Mike Doustdar, President and CEO, Full year 2025 earnings call, 4 February 2026

> "I don't measure our ambition by the number or the size of the acquisition we make." — Maziar Mike Doustdar, President and CEO, Q2 2026 earnings call, 5 August 2026

> "Obesity does not kill. Conditions and complications related to obesity kill" — Maziar Mike Doustdar, President and CEO, Fierce Pharma interview, 11 June 2026


## Where a supplier can help

- **Consumer-style commercial capabilities**: With obesity behaving like a consumer market and a growing self-pay and direct-to-consumer channel, digital marketing, telehealth, pharmacy and subscription partners fit the US access priority.
- **Manufacturing and supply chain**: Capex of around DKK 55 billion in 2026, US plant investments and the Wegovy pill's ex-US rollout create demand for API, fill-finish, automation and logistics suppliers.
- **Cost efficiency after restructuring**: The DKK 8 billion savings programme and lower sales and distribution costs favour vendors that cut operating and commercial costs.
- **R&D productivity**: The merged R&D organisation uses AI and digital tools, and pipeline setbacks raise the value of trial design, data and clinical operations partners.
- **IT security**: Class actions following a June 2026 IT security incident point to demand for security and incident-response services.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Novo Nordisk Annual Report 2025](https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-annual-report-2025.pdf)

Annual report · 2026-02-04

- Danish, foundation-controlled leader in obesity and diabetes care, built on semaglutide (Ozempic, Rybelsus, Wegovy, Wegovy pill); 45.6 million patients reached and 69,505 employees (77,349 in 2024).
- FY 2025 net sales DKK 309,064 million, +10% at CER (+6.4% reported); operating profit DKK 127,658 million, +6% at CER, after around DKK 8 billion of restructuring costs (+13% at CER without them); net profit DKK 102,434 million.
- Two segments: Obesity and Diabetes care DKK 289,456 million (operating margin 43.7%) and Rare disease DKK 19,608 million (6.2%); obesity care DKK 82,347 million (+31% at CER), diabetes care DKK 207,109 million (+4%).
- US Operations DKK 173,166 million (+8% at CER), International Operations DKK 135,898 million (+14%); diabetes value share down 3.6 points to 30.1%, branded obesity volume share 59.6%.
- Strategy refocused on obesity and diabetes; about 9,000 jobs cut for DKK 8 billion of annual savings from 2026; R&D merged; new Strategic Aspirations due at the 21 September 2026 Capital Markets Day.
- Obesity portfolio: Wegovy pill (approved in the US, 16.6% weight loss), Wegovy 7.2 mg (20.7%), CagriSema filed with the FDA, zenagamtide into phase 3, Akero acquisition (efruxifermin for MASH).
- Capex DKK 60.1 billion; intangible investments DKK 30.0 billion; free cash flow DKK 28.3 billion; dividend DKK 11.70; DKK 15 billion buyback for 2026.
- 2026 guidance: adjusted sales and operating profit growth -5% to -13% at CER, on lower US prices (MFN agreement) and semaglutide loss of exclusivity in some markets.
- New Chair Lars Rebien Sørensen after a November 2025 EGM replaced seven board members; CEO Maziar Mike Doustdar since 2025.
- Key risks: semaglutide dependency, US pricing and tariffs, competition and compounders, supply capacity, rising emissions (+19%).

### [Novo Nordisk Financial Report for the First Six Months of 2026 (Company announcement No 48/2026)](https://via.ritzau.dk/files/90446/15075438/486237/en)

Interim report · 2026-08-04

- H1 2026 adjusted sales DKK 148,551 million, +2% at CER; Q2 adjusted sales DKK 78,488 million, +7% at CER. Reported H1 sales DKK 175,311 million include a DKK 26.8 billion US 340B rebate provision reversal.
- Q2 adjusted operating profit DKK 33,389 million, +11% at CER; reported Q2 operating profit -16% after DKK 6.3 billion of pipeline impairments, including monlunabant (DKK 4.0 billion).
- Obesity care H1 DKK 44,064 million, +19% at CER; Diabetes care DKK 95,365 million, -5%; Rare disease DKK 9,122 million, +2%.
- US Operations adjusted H1 sales -4% at CER on lower prices; International Operations +8%, with obesity care +40%.
- Wegovy pill: more than 5 million US prescriptions since its January launch and over 265,000 a week by 17 July; launched in the UAE and UK, approved in the EU. Wegovy HD launched in the US.
- ZEUS (ziltivekimab) failed its primary endpoint; CagriSema was non-inferior to tirzepatide on weight but not on HbA1c in REIMAGINE 4.
- Guidance raised to 0% to -6% at CER for adjusted sales and adjusted operating profit growth (from -4% to -12%); free cash flow now DKK 45-55 billion.
- The US list price of Wegovy and Ozempic falls to USD 675 from 1 January 2027 (about 50% and 35% cuts).

### [Novo Nordisk Q2 2026 Earnings Call (transcript)](https://www.roic.ai/quote/NVO/transcripts/2026-year/2-quarter)

Executive talk · Maziar Mike Doustdar, President and CEO · 2026-08-05

- Doustdar: more than 46 million people served, nearly 5 million on Novo obesity treatments (almost 70% more than a year ago), around 1.5 million on the Wegovy pill worldwide.
- Wegovy pill is "the strongest-ever GLP-1 launch by volume" in the US, with over 5 million prescriptions, around 90% of the oral obesity market and roughly 80% of patients new to GLP-1s.
- US self-pay is about 35% of injectable Wegovy (10%-15% a year ago); injectable volume growth was offset by lower realised prices.
- UK pill launch: around 300,000 patients in three weeks, lifting Novo's obesity share from around 30% to 45%; Germany launches in September.
- ZEUS failure "does not change our strategy"; ARTEMIS and HERMES continue; CagriSema US obesity decision expected end 2026.
- Guidance raised to 0% to -6% at CER; DKK 8 billion savings ahead of plan; headcount around 66,700, down almost 12,000 in a year.
- On M&A, Doustdar is "in every data room" for bolt-ons and does not measure ambition by deal size.

### [Novo Nordisk Full Year 2025 Earnings Call (transcript)](https://www.roic.ai/quote/NVO/transcripts/2025-year/4-quarter)

Executive talk · Maziar Mike Doustdar, President and CEO · 2026-02-04

- 2025: 10% sales growth and 6% operating profit growth; obesity care went from DKK 6 billion in 2019 to DKK 82 billion in 2025.
- Executive changes: Jamey Millar (ex-Optum Specialty Holdings) becomes EVP US Operations; Hong Chow (ex-Merck Healthcare) becomes EVP Product and Portfolio Strategy, replacing Dave Moore and Ludovic Helfgott.
- Wegovy pill launched 5 January at around 50,000 weekly prescriptions after three weeks, mostly self-pay, "over twice that of any prior anti-obesity drug launches" in the US.
- 2026 guidance -5% to -13% at CER: International Operations up mid-single digits, US down in the teens, driven by price (market access, self-pay mix, MFN).
- Capital: around DKK 60 billion capex and DKK 30 billion business development in 2025; over DKK 60 billion of cash returns planned for 2026.
- Doustdar: the pill's 16.6% weight loss versus 12.4% for the rival oral product is the decisive argument; "price reduction in some ways, is our investment for the future".

### ['I'm a lot more optimistic today': Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO](https://www.fiercepharma.com/pharma/if-thats-not-acceleration-i-dont-know-what-novo-nordisk-ceo-doustdar-talks-leadership-new)

Executive talk · Maziar Mike Doustdar, President and CEO · 2026-06-11

- Nine months in, Doustdar is "a lot more optimistic today than the day I got the job", and wants to build skills for "a durable leadership in this new obesity era".
- He sees obesity as "a lot more like a fast consumer goods type of a behavior", unlike insulin, where patients stay on a product for a long time.
- Manufacturing ramp-up is now "second to none"; the Wegovy pill launch (more than 3 million prescriptions, over 80% new to GLP-1s) is his proof of acceleration.
- Novo was "a little ahead of our time" with "beyond weight"; the message is now "weight and beyond", because complications of obesity are what kill.
- He defends CagriSema despite trailing tirzepatide, saying the market is "obsessed with one number", and points to zenagamtide, cagrilintide, triple agonists and efruxifermin.

## Questions about Novo Nordisk

### What does Novo Nordisk do?

Novo Nordisk develops, manufactures and sells treatments for obesity and diabetes, such as Ozempic and Wegovy, and for rare blood and endocrine disorders.

### What was Novo Nordisk's revenue in 2025?

Net sales were DKK 309,064 million in 2025, +10% at CER, with operating profit of DKK 127,658 million.

### How many employees does Novo Nordisk have?

Novo Nordisk had 69,505 employees at end 2025; full-time employees were around 66,700 by Q2 2026 after the restructuring.

### What is Novo Nordisk's strategy?

It has refocused on obesity and diabetes, building a full obesity portfolio of injectables and pills, widening US access through direct-to-consumer channels and cutting about 9,000 jobs to fund growth.

### Who leads Novo Nordisk?

Maziar Mike Doustdar has been President and CEO since 2025, Karsten Munk Knudsen is CFO, and Lars Rebien Sørensen chairs the Board.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
